WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Abbott

AbbottAt Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

www.abbott.com

Abbott RSS Channel

Filters
List of articles in category Abbott
Title Published Date
Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology 17 November 2009
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain 13 November 2009
Abbott Completes Acquisition of Evalve, Inc. 04 November 2009
Abbott completes acquisition acquisition of privately held eye care company Visiogen 29 October 2009
Abbott Completes Visiogen Acquisition 21 October 2009
Abbott Reports 16.5 Percent Earnings Growth in Third Quarter 14 October 2009
Abbott to Acquire Solvay Pharmaceuticals Business 28 September 2009
Results from Abbott's PROSPECT Study Provide New Insight 25 September 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent 14 September 2009
Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 11 September 2009
Abbott Again Named One of the 'Best Places to Launch a Career' by BusinessWeek 08 September 2009
Abbott to Acquire Visiogen, Expanding Vision Care Portfolio 03 September 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets 01 September 2009
Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test 28 August 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 25 August 2009
Abbott Partners With Beech-Nut to Provide New Parents with Nutrition Education and Support 11 August 2009
Abbott to Acquire Nutrition Businesses, Expanding Presence in India 29 July 2009
Abbott and GSK to Collaborate on Molecular Diagnostic Test 14 July 2009
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent 17 June 2009
Abbott Announces Launch of Next-Generation Embolic Protection System 13 June 2009
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
  • End
Tahmeena

Business & Industry

  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed
  • Bayer to accelerate drug discovery with Google Cloud's high-performance compute power
  • NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs

Research & Development

  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic
  • Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations
  • Study identifies potential new approach for treating lupus

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Abbott
  4. Abbott names Robert B. Ford president, chief operating officer

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.